These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 3042307

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment.
    Valensi P, Moura I, Le Magoarou M, Pariès J, Perret G, Attali JR.
    Diabetes Metab; 1997 Feb; 23(1):51-7. PubMed ID: 9059766
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Plasma and urinary C-peptide in the classification of adult diabetics.
    Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppälä P.
    Scand J Clin Lab Invest; 1986 Nov; 46(7):655-63. PubMed ID: 3538365
    [Abstract] [Full Text] [Related]

  • 8. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [Abstract] [Full Text] [Related]

  • 10. Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients.
    Viikari J, Rönnemaa T, Koskinen P.
    Ann Clin Res; 1987 Jun; 19(3):178-82. PubMed ID: 3314647
    [Abstract] [Full Text] [Related]

  • 11. Control of non-insulin dependent diabetes is not correlated with endogenous insulin secretion.
    Lev-Ran A, Hwang D, Barseghian G, Hill LR.
    Diabete Metab; 1986 Dec; 12(6):325-8. PubMed ID: 3545932
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [Abstract] [Full Text] [Related]

  • 14. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
    Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.
    Exp Clin Endocrinol Diabetes; 1998 Jun; 106(2):103-7. PubMed ID: 9628239
    [Abstract] [Full Text] [Related]

  • 15. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ, Castillo MJ, Lefèbvre PJ.
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [Abstract] [Full Text] [Related]

  • 16. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A, Nauck MA, Balena R.
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [Abstract] [Full Text] [Related]

  • 17. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [Abstract] [Full Text] [Related]

  • 18. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB, Madsbad S, Holst JJ.
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [Abstract] [Full Text] [Related]

  • 19. The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes.
    Nosari I, Lepore G, Maglio ML, Cortinovis F, Pagani G.
    J Endocrinol Invest; 1992 Feb; 15(2):143-6. PubMed ID: 1569291
    [Abstract] [Full Text] [Related]

  • 20. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.
    Montgomery TM, Nelson RW, Feldman EC, Robertson K, Polonsky KS.
    J Vet Intern Med; 1996 Feb; 10(3):116-22. PubMed ID: 8743209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.